Egyptian Arthroplasty Surgeons' Antibiotics Usage Awareness

Attitudes of Prophylactic Antibiotic Utilization During Primary Total Hip and Knee Arthroplasty Among Egyptian Joint Replacement Surgeons

Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are procedures successfully applied to manage various end-stage chronic hip and knee diseases, such as osteoarthritis, rheumatoid arthritis, and femoral head avascular necrosis, as well as acute conditions, such as the neck of femur fractures, with excellent long-term functional outcomes. One of the devastating complications after such a procedure is periprosthetic joint infection (PJI). Various precautions are proposed to guard against such complications; one is the administration of perioperative antibiotics. However, injudicious or misuse of antibiotics could lead to the emergence of antimicrobial resistance, further complicating this matter. This is why various scientific and research organizations have proposed guidelines and a consensus for proper antibiotic use in perioperative THA and TKA surgery.

Antibiotic prophylaxis during primary THA and TKA can reduce the risk of PJI and surgical site infections. However, there is a lack of consensus on the optimal dosages and duration of prophylaxis, and guidelines vary among institutions. Alternatives such as extended oral antibiotic prophylaxis and different antibiotic regimens are being explored. International research is needed to establish best practices and determine the potential risks of antibiotic prophylaxis during primary THA and TKA. Unfortunately, the investigators are unaware of such guidelines proposed by any Egyptian health authority to guide and control the proper utilization of antibiotics during orthoapedic practice in general and joint replacement surgeries (THA and TKA) in particular.

Study Overview

• Status: Completed
• Conditions: Infections Joint Prosthetic
• Intervention / Treatment: Other: Questionnaire

Detailed Description

This study will be an Online-based questionnaire investigating surgeons' perspectives on antibiotics utilization during primary total hip and knee arthroplasty surgeries and investigate their thoughts about the necessity for developing local guidelines.

• Study Type: Observational
• Enrollment (Actual): 105

Contacts and Locations

Study Locations

• Egypt
  • Assiut, Egypt
    • Assuit Faculty of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Active practicing Egyptian joint replacement surgeons

Description

Inclusion criteria:

All Egyptian registered members of the Egyptian Pelvis and Hip Society, practicing Egyptian joint replacement surgeons (performing surgeries as a leading surgeon) who are willing to participate

Exclusion criteria:

• Members not listed in the E-mail directory of the society
• Surgeons refusing to participate
• Young surgeons who are not practicing independently

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To determine the type of antibiotics administration during primary total hip and knee arthroplasty	The type of antibiotics will be determined as follows: the name of the antibiotic (brand or generic), and if single or dual antibiotics are used. These will be presented as numbers and percentages.	2 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To determine the dose of antibiotics administered during primary total hip and knee arthroplasty	The dose of antibiotics will be determined as grams or milligrams. Furthermore, the number of doses will be reported	2 months
To determine the timing of antibiotics administration during primary total hip and knee arthroplasty	Regarding the timing, preoperative antibiotic administration will be reported in minutes	2 months
To determine the length of antibiotics administration during primary total hip and knee arthroplasty	the length of antibiotic administration postoperatively will be calculated in days.	2 months

Collaborators and Investigators

• Sponsor: South Valley University
• Collaborators: Assiut University
• Investigators: Study Chair: Ahmed Abd El-Aal, MD, Assiut University

Study record dates

Study Major Dates

• Study Start (Actual): June 15, 2024
• Primary Completion (Actual): August 30, 2024
• Study Completion (Actual): September 30, 2024

Study Registration Dates

• First Submitted: May 23, 2024
• First Submitted That Met QC Criteria: June 9, 2024
• First Posted (Actual): June 11, 2024

Study Record Updates

• Last Update Posted (Actual): October 16, 2024
• Last Update Submitted That Met QC Criteria: October 13, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: 04-2024-300439

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No